Validation of the Zigzag Tracking Task Test for the Evaluation of Handwriting Difficulties in Writer's Cramp

Dystonic Disorder Clinical Trial

— LabyDys  

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02882295
• Other study ID #: SSA_2016_10
• Status: Terminated
• Start date: July 5, 2016
• Est. completion date: November 15, 2017

Study information

• Verified date: April 2022
• Source: Fondation Ophtalmologique Adolphe de Rothschild
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Writer's cramp (WC) is a task specific dystonia that occurs from the moment patient starts writing. It leads to partial or complete inability to use the hand only during the handwriting gesture. It is characterized by the appearance of cramps or spasms of certain muscles of the hand and/or forearm.

Clinical scales currently use for the assessment of WC fail to accurately reflect changes in the characteristics of handwriting in response to treatments (Botulinum Neurotoxin injections and / or retraining therapy).

The Zigzag Tracking Task (ZZTT), easy to use in current practice provides useful information in terms of speed and precision of handwriting gesture. This timed handwriting test is to follow with a pen a zigzag path beset with obstacles to avoid. It permits to evaluate the time in seconds required to carry out the zigzag path and count the number of errors (output path and contacts with obstacles). The investigators propose to validate the ZZTT for the assessment of the handwriting gesture of WC.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 23
• Est. completion date: November 15, 2017
• Est. primary completion date: November 15, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• scholarship in French language, at least until 16 years old

• writer's cramp (diagnostic confirmed by a neurologist specialized in movement disorders)

• prescription of botulinum neurotoxin injection

• prescription de novo or absence of injection in the last 3 months

• informed consent

• medical insurance coverage

Exclusion Criteria:

• writing tremor

• -other neurological disease with effect on handwriting

• pain or traumatism of the upper limb, with effect on handwriting

• non-corrected visual disturbances

• patient living outside the region where the study will be held (Ile-de-France)

• participation in another research with a potential impact on evaluation criteria

• pregnant or breast feeding patient

• patient under judiciary protection

Related Conditions & MeSH terms

• Dystonia
• Dystonic Disorder
• Dystonic Disorders

Intervention

Other:
• Validation of a handwriting scale

Locations

Country	Name	City	State
France	Fondation Ophtalmique Adolphe de Rothschild	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Fondation Ophtalmologique Adolphe de Rothschild

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	hand-writing speed	speed and accuracy of handwriting	immediate